Highest-materiality recent filing
VSee Health raises $575,550 via two convertible notes with discounted conversion
ClearThink Note: $280,000 principal ($30,000 OID), 10% interest, due June 22, 2027, conversion at 85% of lowest closing price over 10 days prior to conversion, floor $0.01.
VSee Health enters $10M standby equity purchase agreement with YA II PN
Company can require investor to buy up to $10M of common stock through June 2029.
VSee Health sells VSee Lab to co-CEO Chen; Chen resigns, Aisiku becomes sole CEO and Chairman
VSee Health sold all equity of VSee Lab to Milton Chen in exchange for Chen's 2,870,069 shares of VSEE common stock, effectively retiring those shares.
VSee Health to acquire 10% of GoMyRx for $2M in stock; enters managed services agreement
VSEE to purchase $2.0M of GMRx common stock via issuance of own stock, representing 10% ownership.
VSee Health reports pro forma equity of $9.5M, regains Nasdaq continued listing compliance
Pro forma equity of $9.5M as of Dec 1, 2025, up from ($18,488) deficit at Dec 31, 2024.
VSee Health designates Series B Convertible Preferred Stock with $0.65 conversion price
Filed Certificate of Designation for 2,000 shares of Series B Preferred Stock, $1,000 stated value.
VSEE Health regains Nasdaq equity compliance; pro forma equity $13.2M vs $2.5M minimum
Stockholders' deficit of $18,488 at Dec 31, 2024 was below Nasdaq's $2.5M minimum for continued listing.
VSee Health raises ~$6M in private placement of common shares and warrants
Gross proceeds of ~$6M from sale of 9.8M shares (or pre-funded warrants) and 19.7M common warrants at $0.61/unit.
VSee Health issues $217K convertible note at 18% interest, $0.48 conversion price, plus 50K shares
Initial principal $217,391; net proceeds $201,000 (8% OID) to VSee Health from M2B Funding Corp.
VSee Health warrants exchange with Alta: 2.25M warrants for 2.175M shares
Exchanged 2,250,000 IPO warrants with Alta Partners for 2,175,000 common shares; 130,000 warrants exercised for cash.
VSee Health lowers convertible note conversion price to $0.75 per share
Amendment to $2,222,222 senior secured convertible promissory note dated Sept 30, 2024.
VSee Health issues $133k secured note, terminates equity line with Dominion
Issued $133,333.33 secured note for $120,000 (10% OID), 5% interest, matures May 20, 2026, non-convertible.
VSee Health dismisses auditor Withum, appoints WWC as new independent auditor
Dismissed WithumSmith+Brown as auditor effective Sept 15, 2025; no disagreements or reportable events except material weaknesses from 2024 10-K.
Nasdaq staff notified VSee on Sep 24, 2025 that common stock bid price closed below $1.00 for 30 consecutive business days.
VSee Health receives additional Nasdaq delisting notice for equity deficiency; hearing Sept 9
Stockholders' equity of -$18,488 as of Dec 31, 2024, below the $2.5M minimum for continued listing.
VSee Health restates 2023-2024 financials due to 12 errors; material weaknesses in controls
Prior annual and interim financial statements from 2023 and 2024 periods are no longer reliable and will be restated.
VSee Health receives Nasdaq deficiency for late Q2 10-Q; delisting hearing Sept 9
Received additional Nasdaq deficiency notice on Aug 20, 2025 for failure to timely file Q2 2025 Form 10-Q.
VSee Health receives Nasdaq delisting determination; trading suspended Aug 14
Nasdaq denied VSee's request to continue listing due to late Form 10-K and 10-Q filings.
VSee Health receives Nasdaq delisting notice for late 10-Q filing
Nasdaq staff notified VSEE on May 23, 2025 of non-compliance with Listing Rule 5250(c)(1) due to failure to timely file Form 10-Q for period ended March 31, 2025.
VSee Health receives Nasdaq delisting notice for failure to file 2024 10-K
Received Nasdaq notice on April 25, 2025 for non-compliance with Listing Rule 5250(c)(1) due to late Form 10-K.
VSee Health issues $555.6K secured note and $108.7K note; amends equity purchase agreement
Issued senior secured note for $555,555.56 at 5% interest, maturing Nov 1, 2025, plus 100,000 commitment shares.
VSee Health announces ~$935K in medtech contracts for remote device support
Contracts with multiple medical device companies total ~$935,000.
VSee Health nets $6M government contract and $160K Florida health system deal
Awarded a multi-year government contract with $6M allocated for the first year to deploy customizable telehealth platform.
VSee Health partners with AbundaBox to launch AbundaLife health record platform at $34/year
Strategic partnership with AbundaBox to launch AbundaLife, a health record management platform.
VSee Health Q3 revenue up 131% to $3.4M; net loss $51.8M on $55M goodwill impairment
Q3 2024 revenue $3.4M (up 131% YoY); 9-month revenue $6.6M (+51%).
Principal $2,222,222.22 at 10% interest, due March 30, 2026; secured by substantially all assets including IP.
VSee Health Q2 revenue up 33% to $1.7M; net loss narrows to $0.3M
Revenue $1.7M (+33% YoY); net loss $0.3M ($0.06/shr) vs $0.4M net loss in prior-year quarter.
Received Nasdaq notice on Sept 6, 2024 due to missing Q2 2024 Form 10-Q deadline; must respond by Nov 5, 2024.
Mr. Chen’s resignation was not because of any disagreement between Mr. Chen and the Company on any matter relating to the Company’s operations, policies or practices.
Dr. Imoigele Aisiku, the Company’s co-Chief Executive Officer, was appointed as the sole Chief Executive Officer and the chairman of the board of directors of the Company, effective immediately.
On July 17, 2024, the Board of Directors (the “Board”) of VSee Health, Inc. (the “Company”) voted to increase the size of the Board from five to seven members, and to appoint Cydonii V. Fairfax and David L. Wickersham as new Class III directors to fill the vacancies created by such increase, with such appointments effective July 17, 2024.
On July 17, 2024, the Board of Directors (the “Board”) of VSee Health, Inc. (the “Company”) voted to increase the size of the Board from five to seven members, and to appoint Cydonii V. Fairfax and David L. Wickersham as new Class III directors to fill the vacancies created by such increase, with such appointments effective July 17, 2024.
Milton Chen, Imoigele Aisiku, and Colin O’Sullivan were appointed as directors of the Company.
Imoigele Aisiku was appointed Co-Chief Executive Officer of the Company
Scott Wolf, Frank Ciufo, and George McNellage ceased serving on the Board
Milton Chen was appointed Co-Chief Executive Officer of the Company
Scott Wolf, Frank Ciufo, and George McNellage ceased serving on the Board
Milton Chen, Imoigele Aisiku, and Colin O’Sullivan were appointed as directors of the Company.
Milton Chen, Imoigele Aisiku, and Colin O’Sullivan were appointed as directors of the Company.
Scott Wolf, Frank Ciufo, and George McNellage ceased serving on the Board
Max materiality 0.90 · Median 0.60 · Most common event other_material